Youyou Yan, Zhao Cao, Ming Yang, He Li, Hongfei Wei, Yao Fu, Dandan Song, Liying Wang, Yongli Yu
Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
International immunopharmacology 2012 FebAlthough being promising tumor vaccine candidates in animal models, heat shock protein (HSP)-based tumor vaccines have not yet succeeded in the clinical trials, implying the necessity to be formulated with appropriate adjutants to enhance their immunogenicity. In this study, we investigated whether a B-class CpG ODN (BW006), a TLR9 agonist, could facilitate HSP65-Her2, a recombinant protein between mycobacterial HSP65 and Her2-derived peptide, to induce vigorous anti-tumor activity against Her2 positive tumors in mice both prophylactically and therapeutically. It was found that BW006 could enhance prophylactic and therapeutic effect of HSP65-Her2 with improved survival of the mice bearing Her2(+) B16 melanoma and HSP65-Her2 specific Th1 response. Copyright © 2011 Elsevier B.V. All rights reserved.
Youyou Yan, Zhao Cao, Ming Yang, He Li, Hongfei Wei, Yao Fu, Dandan Song, Liying Wang, Yongli Yu. A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice. International immunopharmacology. 2012 Feb;12(2):402-7
PMID: 22222115
View Full Text